Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4257496 · 1 trial · 7 indications
| Arm | Type | Description |
|---|---|---|
| LY4257496 Phase 1a Dose Escalation (Cohort A1) | EXPERIMENTAL | LY4257496 administered intravenously (IV) |
| LY4257496 Phase 1a Dose Optimization (Cohort A2) | EXPERIMENTAL | LY4257496 administered IV |
| LY4257496 + Standard of Care Phase 1b Cohort B | EXPERIMENTAL | Tumor specific cohort will receive LY4257496 alone or with standard of care anticancer therapy(ies) |
| LY4257496 Phase 1b Cohort C | EXPERIMENTAL | Tumor specific cohort will receive LY4257496 |
| LY4257496 Phase 1b Cohort D | EXPERIMENTAL | Tumor specific cohort will receive LY4257496 |
| Name | Type | Description |
|---|---|---|
| LY4257496 | DRUG | Administered IV |
| Standard of Care Anticancer Therapies | DRUG | Fulvestrant, Imlunestrant, Aromatase Inhibitors, Capecitabine, Abemaciclib |
| LY4257529 | DIAGNOSTIC_TEST | Administered IV at select sites |
Inclusion Criteria: * Must have histologically or cytologically proven diagnosis of locally advanced, unresectable, or metastatic cancer. * Must be assessed by computed tomography (CT)/magnetic resonance imaging (MRI) to confirm at least 1 of the following: * At least 1 measurable target lesion ...
LY4257496 is an investigational small molecule being studied for the treatment of breast neoplasms and other advanced solid tumors. It is in Phase 1 clinical development and has not been approved for any indication. Eli Lilly and Company is evaluating it in a study that also includes colorectal, prostate, endometrial, stomach, and esophageal cancers.
LY4257496 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The company is the sole sponsor of the Phase 1 OMNIRAY study evaluating the compound in participants with cancer.
LY4257496 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA or any other regulatory authority. The only registered trial is a Phase 1 study that is currently recruiting participants.
LY4257496 is being evaluated in one clinical trial, NCT07114601, titled A Study of LY4257496 in Participants With Cancer (OMNIRAY). The Phase 1 trial is recruiting and plans to enroll 421 participants across the United States, Canada, China, France, Germany, Japan, and Spain.
Yes, the Phase 1 OMNIRAY trial of LY4257496 is biomarker selected, meaning enrollment is guided by specific molecular characteristics. The study is controlled and enrolls adults 18 years and older with breast neoplasms, colorectal neoplasms, prostate neoplasm, endometrial neoplasms, neoplasm metastasis, stomach neoplasms, or esophageal neoplasms.